MX387232B - Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. - Google Patents
Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.Info
- Publication number
- MX387232B MX387232B MX2020004283A MX2020004283A MX387232B MX 387232 B MX387232 B MX 387232B MX 2020004283 A MX2020004283 A MX 2020004283A MX 2020004283 A MX2020004283 A MX 2020004283A MX 387232 B MX387232 B MX 387232B
- Authority
- MX
- Mexico
- Prior art keywords
- pyridinecarbonyl
- derivatives
- therapeutic uses
- compounds
- trpc6
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La invención se refiere a compuestos de fórmula (I), Véase formula: y a sales farmacéuticamente aceptables de los mismos, en la que R1 a R7,A, Y y L son tal como se definen en el presente documento. La invención también se refiere a composiciones farmacéuticas que comprenden estos compuestos, a métodos de uso de estos compuestos en el tratamiento de diversas enfermedades y trastornos, procedimientos para preparar estos compuestos y productos intermedios útiles en estos procedimientos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577883P | 2017-10-27 | 2017-10-27 | |
| US201862628313P | 2018-02-09 | 2018-02-09 | |
| PCT/EP2018/079276 WO2019081637A1 (en) | 2017-10-27 | 2018-10-25 | CARBONYL PYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USES AS TRPC6 INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020004283A MX2020004283A (es) | 2021-10-21 |
| MX387232B true MX387232B (es) | 2025-03-18 |
Family
ID=64270818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004283A MX387232B (es) | 2017-10-27 | 2018-10-25 | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US10800757B2 (es) |
| EP (2) | EP3786160B1 (es) |
| JP (2) | JP7217273B6 (es) |
| KR (2) | KR20200125758A (es) |
| CN (1) | CN111527078B (es) |
| AU (2) | AU2018355743B2 (es) |
| CA (1) | CA3078769A1 (es) |
| CL (2) | CL2020001097A1 (es) |
| CY (1) | CY1126109T1 (es) |
| DK (2) | DK3700902T3 (es) |
| ES (2) | ES2946274T3 (es) |
| FI (1) | FI3700902T3 (es) |
| HR (2) | HRP20220991T1 (es) |
| HU (2) | HUE059450T2 (es) |
| IL (2) | IL274039B (es) |
| LT (2) | LT3786160T (es) |
| MX (1) | MX387232B (es) |
| MY (1) | MY202126A (es) |
| PE (1) | PE20210154A1 (es) |
| PH (1) | PH12020550503A1 (es) |
| PL (2) | PL3786160T3 (es) |
| PT (2) | PT3700902T (es) |
| RS (2) | RS63535B1 (es) |
| SA (1) | SA520411843B1 (es) |
| SG (2) | SG11202003367TA (es) |
| SI (2) | SI3700902T1 (es) |
| TW (2) | TWI780246B (es) |
| UA (1) | UA128474C2 (es) |
| WO (1) | WO2019081637A1 (es) |
| ZA (1) | ZA202002372B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3786160B1 (en) | 2017-10-27 | 2022-07-13 | Boehringer Ingelheim International GmbH | Pyridine derivatives and therapeutic uses thereof as trpc6 inhibitors |
| EP3752499B1 (en) * | 2018-02-15 | 2024-03-27 | Boehringer Ingelheim International GmbH | Inhibitors of trpc6 |
| EP3752503A1 (en) * | 2018-02-16 | 2020-12-23 | Boehringer Ingelheim International GmbH | Inhibitors of trpc6 |
| IL315313A (en) * | 2018-08-24 | 2024-10-01 | Xeniopro GmbH | Aromatic molecules for use in the treatment of pathological conditions |
| US12156874B2 (en) * | 2019-04-12 | 2024-12-03 | Boehringer Ingelheim International Gmbh | Inhibitors of TRPC6 |
| JP7594274B2 (ja) | 2019-10-24 | 2024-12-04 | 国立大学法人大阪大学 | 難聴の予防および／または治療用医薬組成物 |
| EP4103245A1 (en) | 2020-02-11 | 2022-12-21 | Klinikum rechts der Isar der Technischen Universität München | Administration of calcium channel trpc6 inhibitors using balloons, stents or other medical devices |
| AR121846A1 (es) * | 2020-04-16 | 2022-07-13 | Teijin Pharma Ltd | Derivado de arilo o heteroarilo |
| US20230149393A1 (en) * | 2020-04-16 | 2023-05-18 | Boehringer Ingelheim International Gmbh | Inhibitors of trpc6 for treating respiratory conditions |
| CN113105318B (zh) * | 2021-02-23 | 2022-05-20 | 中山大学 | 一种2,2-二氟环丁烷-1-羧酸的制备方法及应用 |
| AU2022366192A1 (en) | 2021-10-15 | 2024-02-29 | Boehringer Ingelheim International Gmbh | Trpc6 inhibitory compounds for treating sepsis |
| JP2025023360A (ja) * | 2021-12-06 | 2025-02-17 | 国立大学法人 熊本大学 | Ｔｒｐｃ６の発現を抑制する方法 |
| WO2025042707A1 (en) | 2023-08-18 | 2025-02-27 | Boehringer Ingelheim International Gmbh | Inhibitors of trpc6 for treating focal segmental glomerulosclerosis |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05503517A (ja) | 1989-12-18 | 1993-06-10 | バージニア・コモンウェルス・ユニバーシティ | シグマレセプターリガンド及びその用途 |
| PT100639A (pt) | 1991-06-27 | 1993-09-30 | Univ Virginia Commonwealth | Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina |
| CZ141795A3 (en) | 1992-12-02 | 1995-11-15 | Pfizer | 4-substituted catechol diethers as such and for treating diseases and pharmaceutical preparations based thereon |
| ES2300151T3 (es) | 1998-09-22 | 2008-06-01 | Astellas Pharma Inc. | Derivados de cianofenilo. |
| US6376515B2 (en) | 2000-02-29 | 2002-04-23 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor Xa |
| IL153884A0 (en) | 2000-07-20 | 2003-07-31 | Neurogen Corp | Capsaicin receptor ligands |
| JP4186518B2 (ja) * | 2001-06-15 | 2008-11-26 | アステラス製薬株式会社 | フェニルピリジン誘導体 |
| WO2002102778A1 (fr) | 2001-06-15 | 2002-12-27 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de phenylpyridinecarbonylpiperazine |
| NI200300045A (es) | 2002-04-26 | 2005-07-08 | Pfizer Prod Inc | Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa. |
| DE10222291A1 (de) | 2002-05-18 | 2003-11-27 | Schlafhorst & Co W | Faserbandzuführeinrichtung |
| CN1150176C (zh) | 2002-05-22 | 2004-05-19 | 上海医药工业研究院 | 芳烷酮哌嗪衍生物及其应用 |
| CA2581745A1 (en) | 2004-10-13 | 2006-04-27 | Neurogen Corporation | Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor |
| DE102005044814A1 (de) | 2005-05-19 | 2006-11-23 | Grünenthal GmbH | Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| AR056582A1 (es) | 2005-10-28 | 2007-10-10 | Lilly Co Eli | COMPUESTOS DE PIRAZOLIL UREA CON ACTIVIDAD INHIBITORIA DE CINASA P38 Y FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE |
| WO2007075629A2 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists |
| JP5019768B2 (ja) | 2006-03-23 | 2012-09-05 | 独立行政法人科学技術振興機構 | 新規低分子化合物およびその製造方法 |
| US8536168B2 (en) | 2007-03-15 | 2013-09-17 | Novartis Ag | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway |
| JP5082538B2 (ja) | 2007-03-28 | 2012-11-28 | Ｄｉｃ株式会社 | ピペラジン化合物 |
| JP2012512877A (ja) | 2008-12-18 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | セロトニン５−ｈｔ２ｂ受容体阻害剤 |
| US20100234603A1 (en) | 2009-03-13 | 2010-09-16 | Xin Linghu | Process for Making Substituted Aryl Sulfone Intermediates |
| US20110039850A1 (en) | 2009-08-12 | 2011-02-17 | Mhairi Copland | Leukemia Treatment |
| CN102686579A (zh) | 2009-10-09 | 2012-09-19 | Irm责任有限公司 | 作为gpr119活性调节剂的化合物和组合物 |
| WO2011062939A1 (en) | 2009-11-18 | 2011-05-26 | Novartis Ag | Methods and compositions for treating solid tumors and other malignancies |
| CA2791738C (en) | 2010-03-01 | 2020-06-09 | Gtx, Inc. | Aryl imidazolyl compounds for the treatment of cancer |
| US8816079B2 (en) | 2010-04-27 | 2014-08-26 | Mitsubishi Tanabe Pharma Corporation | Amide derivative and use thereof as medicine |
| WO2011143365A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
| CN103201267B (zh) | 2010-07-29 | 2016-08-17 | 里格尔药品股份有限公司 | Ampk-激活性杂环化合物以及其使用方法 |
| US9586928B2 (en) | 2011-05-16 | 2017-03-07 | The Scripps Research Institute | Modulators of the nuclear hormone receptor ROR |
| JP5800786B2 (ja) | 2011-10-26 | 2015-10-28 | 田辺三菱製薬株式会社 | 新規アミド誘導体を有効成分として含有する医薬組成物 |
| US9139585B2 (en) | 2011-10-31 | 2015-09-22 | Merck Sharp & Dohme Corp. | Inhibitors of the Renal Outer Medullary Potassium channel |
| CN103360343B (zh) | 2012-03-30 | 2017-04-19 | 凯惠药业(上海)有限公司 | 一种哌嗪酰胺类化合物的制备方法 |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| AR096423A1 (es) * | 2013-05-27 | 2015-12-30 | Hoffmann La Roche | Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona |
| US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| KR20160100408A (ko) | 2014-01-06 | 2016-08-23 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 글루타미나제 저해제 |
| WO2015199206A1 (ja) | 2014-06-27 | 2015-12-30 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する６員環誘導体 |
| AR102537A1 (es) | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
| MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| WO2017066705A1 (en) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
| CN107176927B (zh) | 2016-03-12 | 2020-02-18 | 福建金乐医药科技有限公司 | 组蛋白去甲基化酶lsd1抑制剂 |
| RS64261B1 (sr) | 2016-03-16 | 2023-07-31 | Kura Oncology Inc | Supstituisani derivati tieno[2,3-d]pirimidina kao inhibitori menin-mll i načini upotrebe |
| RU2019101420A (ru) | 2016-06-20 | 2020-07-21 | Ратгерс, Де Стейт Юниверсити Оф Нью Джерси | Терапевтические соединения |
| CN107540636A (zh) | 2016-06-29 | 2018-01-05 | 成都贝斯凯瑞生物科技有限公司 | 一种含氮杂环衍生物及其应用 |
| CN106317050B (zh) * | 2016-08-24 | 2018-11-23 | 烟台大学 | 一种苯基噻唑衍生物及其制备方法与应用 |
| JPWO2018159827A1 (ja) | 2017-03-03 | 2020-01-09 | 国立大学法人京都大学 | 植物ステロイドホルモン（ブラシノライド）様活性をもつ非ステロイド化合物の創製 |
| TW201902875A (zh) | 2017-03-15 | 2019-01-16 | 美商亞瑟尼克斯公司 | 聯芳基哌啶醯胺化合物及其使用方法 |
| EP3786160B1 (en) | 2017-10-27 | 2022-07-13 | Boehringer Ingelheim International GmbH | Pyridine derivatives and therapeutic uses thereof as trpc6 inhibitors |
| KR102625984B1 (ko) * | 2017-11-16 | 2024-01-18 | 프린시피아 바이오파마, 인코퍼레이티드 | 면역프로테아좀 억제제 |
| EP3752499B1 (en) | 2018-02-15 | 2024-03-27 | Boehringer Ingelheim International GmbH | Inhibitors of trpc6 |
| EP3752503A1 (en) | 2018-02-16 | 2020-12-23 | Boehringer Ingelheim International GmbH | Inhibitors of trpc6 |
-
2018
- 2018-10-25 EP EP20197194.2A patent/EP3786160B1/en active Active
- 2018-10-25 DK DK18800513.6T patent/DK3700902T3/da active
- 2018-10-25 FI FIEP18800513.6T patent/FI3700902T3/fi active
- 2018-10-25 ES ES18800513T patent/ES2946274T3/es active Active
- 2018-10-25 PE PE2020000424A patent/PE20210154A1/es unknown
- 2018-10-25 RS RS20220752A patent/RS63535B1/sr unknown
- 2018-10-25 SI SI201830924T patent/SI3700902T1/sl unknown
- 2018-10-25 PL PL20197194.2T patent/PL3786160T3/pl unknown
- 2018-10-25 SG SG11202003367TA patent/SG11202003367TA/en unknown
- 2018-10-25 EP EP18800513.6A patent/EP3700902B8/en active Active
- 2018-10-25 UA UAA202003145A patent/UA128474C2/uk unknown
- 2018-10-25 HU HUE20197194A patent/HUE059450T2/hu unknown
- 2018-10-25 ES ES20197194T patent/ES2924933T3/es active Active
- 2018-10-25 HU HUE18800513A patent/HUE062460T2/hu unknown
- 2018-10-25 DK DK20197194.2T patent/DK3786160T3/da active
- 2018-10-25 WO PCT/EP2018/079276 patent/WO2019081637A1/en not_active Ceased
- 2018-10-25 US US16/170,154 patent/US10800757B2/en not_active Ceased
- 2018-10-25 MY MYPI2020001894A patent/MY202126A/en unknown
- 2018-10-25 KR KR1020207031025A patent/KR20200125758A/ko not_active Withdrawn
- 2018-10-25 PT PT188005136T patent/PT3700902T/pt unknown
- 2018-10-25 KR KR1020207014013A patent/KR102724066B1/ko active Active
- 2018-10-25 CA CA3078769A patent/CA3078769A1/en active Pending
- 2018-10-25 US US16/170,178 patent/US10889568B2/en active Active
- 2018-10-25 PT PT201971942T patent/PT3786160T/pt unknown
- 2018-10-25 RS RS20230382A patent/RS64271B1/sr unknown
- 2018-10-25 LT LTEP20197194.2T patent/LT3786160T/lt unknown
- 2018-10-25 AU AU2018355743A patent/AU2018355743B2/en active Active
- 2018-10-25 HR HRP20220991TT patent/HRP20220991T1/hr unknown
- 2018-10-25 TW TW107137733A patent/TWI780246B/zh active
- 2018-10-25 HR HRP20230502TT patent/HRP20230502T1/hr unknown
- 2018-10-25 MX MX2020004283A patent/MX387232B/es unknown
- 2018-10-25 JP JP2020523445A patent/JP7217273B6/ja active Active
- 2018-10-25 SI SI201830732T patent/SI3786160T1/sl unknown
- 2018-10-25 TW TW109138850A patent/TWI780511B/zh active
- 2018-10-25 PL PL18800513.6T patent/PL3700902T3/pl unknown
- 2018-10-25 SG SG10202011632RA patent/SG10202011632RA/en unknown
- 2018-10-25 LT LTEPPCT/EP2018/079276T patent/LT3700902T/lt unknown
- 2018-10-25 CN CN201880070122.4A patent/CN111527078B/zh active Active
-
2020
- 2020-04-19 IL IL274039A patent/IL274039B/en unknown
- 2020-04-23 CL CL2020001097A patent/CL2020001097A1/es unknown
- 2020-04-26 SA SA520411843A patent/SA520411843B1/ar unknown
- 2020-04-27 PH PH12020550503A patent/PH12020550503A1/en unknown
- 2020-05-04 ZA ZA2020/02372A patent/ZA202002372B/en unknown
- 2020-09-22 IL IL277493A patent/IL277493B/en unknown
- 2020-10-02 CL CL2020002562A patent/CL2020002562A1/es unknown
- 2020-10-06 AU AU2020250185A patent/AU2020250185B2/en active Active
- 2020-10-08 JP JP2020170563A patent/JP6979502B2/ja active Active
- 2020-12-08 US US17/115,667 patent/US20210163449A1/en not_active Abandoned
-
2021
- 2021-05-28 US US17/334,097 patent/USRE49699E1/en active Active
-
2023
- 2023-06-07 CY CY20231100270T patent/CY1126109T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX387232B (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| MX2023001876A (es) | Derivados de rapamicina. | |
| CO2017013708A2 (es) | Macrociclos peptídicos contra acinetobacter baumannii. | |
| MX2018005890A (es) | Composiciones para tratar atrofia muscular espinal. | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| DOP2015000158A (es) | Inhibidores de prmt5 y sus usos | |
| UY35551A (es) | Derivados heteroarilos como inhibidores de aldosterona sintasa | |
| ECSP15012804A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| NI201400107A (es) | Compuestos de heterociclilo como inhibidores de mek | |
| CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| UY34974A (es) | Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| DOP2016000276A (es) | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS | |
| CR20130371A (es) | IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS | |
| MX2017000926A (es) | Acidos carboxilicos heterociclicos como activadores de guanilato ciclasa soluble. | |
| CO7280475A2 (es) | Derivados de azaindol que actuan como inhibidores de pi3k | |
| UY36228A (es) | Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen | |
| ECSP22038509A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
| CL2021000844A1 (es) | Compuestos de indolinona para uso como inhibidores de map4k1 | |
| UY36124A (es) | Derivados de carboxamida | |
| CL2022002975A1 (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| CL2017000827A1 (es) | Inhibidores de aldosterona sintasa | |
| CR20160600A (es) | Quinolizione derivados como inhibidores pi3k | |
| MX2019004484A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
| UY36123A (es) | Derivados de carboxamida | |
| CO2020005885A2 (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk-2 |